Références bibliographiques

[1] D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppres- sion or conventional management in patients with newly diagnosedCrohn’s disease: anopen randomisedtrial. The Lancet. 2008;371(9613):660-7.

[2] Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris Definition of Early Crohn’s Disease for Disease-Modification Trials: Re- sults of an International ExpertOpinion Process. Am J Gastroenterol. déc 2012;107(12):1770-6.

[3] Ben-Horin S, Novack L, Mao R, et al. Efficacy of Biologic Drugs in Short- Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Control- led Trials. Gastroenterology. 29 oct 2021;S0016-5085(21)03709-4.

[4] Cosnes J, Cattan S, Blain A, et al. Long-Term Evolution of Disease Beha- viorof Crohn’sDisease: InflammBowel Dis.juill 2002;8(4):244-50.

[5] Tsai L, Ma C, Dulai PS, et al. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population- Based Cohorts. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. oct 2021;19(10):2031-2045.e11.

[6] Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’sdi- sease digestive damage score, the Lémann score. Inflamm Bowel Dis.juin 2011;17(6):1415-22.

[7] Ungaro RC, Aggarwal S, Topaloglu O, et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. mai 2020;51(9):831-42.

[8] Ungaro RC, Yzet C, Bossuyt P, etal.Deep Remission at 1 Year Prevents Pro- gression of EarlyCrohn’s Disease. Gastroenterology. juill 2020;159(1):139-47.

[9] Allen PB, Gower-Rousseau C, Danese S, et al. Preventing disability in in- flammatory bowel disease.Ther Adv Gastroenterol. nov 2017;10(11):865-76.

[10] Tannoury J, Nachury M, Martins C, et al. Determinants of IBD- related disability: a cross-sectional survey from the GETAID. Aliment Pharmacol Ther. 2021;53(10):1098-107.

[11] Yzet C, Brazier F, Sebbagh V, et al. Fumery M. Complete endoscopic healing is associated with lower disability than partial endoscopic healing in Crohn's disease: A prospective multicenter study. Clin Res Hepatol Gastroen- terol. 2022 Apr;46(4):101887

[12] Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the Inflam- matory Bowel Disease Disability Index in a population-based cohort. Gut. 1 avr 2017;66(4):588-96.

[13] Gordon IO, Agrawal N, Willis E, et al. Fibrosis in ulcerative colitis is direct- ly linked to severity and chronicity of mucosal inflammation. Aliment Phar- macol Ther. avr2018;47(7):922-39.

[14] Solitano V, D’Amico F, Zacharopoulou E, et al. Early Intervention in Ulce- rative Colitis:Ready for PrimeTime? J Clin Med. 14 août 2020;9(8):2646.

[15] Peyrin-Biroulet L, Germain A, Patel AS, et al. Systematic review: out- comes and post- operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44(8):807-16.

[16] Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acutesevere colitis. J Crohns Colitis.oct 2010;4(4):431-7.

[17] Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selec- ting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 1 avr 2021;160(5):1570-83